Lesley J. Burgess

Stellenbosch, WC, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.

Journal: The New England journal of medicine

Published: August 31, 2026

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

Journal: JAMA cardiology

Published: July 03, 2024

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.

Journal: JAMA cardiology

Published: September 13, 2023

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.

Journal: JACC. Heart failure

Published: September 09, 2022

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.

Journal: Annals of internal medicine

Published: June 06, 2022

Evinacumab in Patients with Refractory Hypercholesterolemia.

Evinacumab in Patients with Refractory Hypercholesterolemia.

Journal: The New England journal of medicine

Published: November 16, 2020

Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study.

Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study.

Journal: Cardiovascular journal of Africa

Published: March 11, 2019

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.

Journal: European heart journal

Published: November 23, 2014

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Journal: Circulation

Published: November 19, 2014

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: October 06, 2014

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Journal: The New England journal of medicine

Published: April 01, 2014

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

Journal: PloS one

Published: June 22, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026